12 results about "Nasal Diseases" patented technology

The present invention discloses a composition for improving rhinitis symptoms and nasal cleaning, as well as its preparation method and application. The composition comprises, by weight, 0.1 to 7 parts of yeast β-glucan and 0.1 to 6 parts of mussel mucin. The present invention prepares a composition for improving rhinitis symptoms and nasal cleaning by rationally combining ultra-low molecular weight yeast β-glucan, low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan, high molecular weight yeast β-glucan, and mussel mucin. The composition can be effectively used for nasal cleaning of patients with nasal diseases such as acute rhinitis, chronic rhinitis, allergic rhinitis, nasal polyps, sinusitis, etc., and can also be used for nasal cleaning after nasal tumor surgery or chemotherapy.

The invention discloses a method for constructing an animal model of a nasal mucosa specific expression target protein. The invention provides a method for constructing a mouse model of a nasal mucosa specific expression target protein, which comprises the following steps: replacing an Obp1a gene termination codon in a mouse genome with a target protein coding gene without causing frameshift mutation, thereby obtaining the mouse model of the nasal mucosa specific expression target protein. By adopting an optimized gene editing technology and a nasal mucosa Obp1a specific promoter, the target protein is ensured to be highly expressed only in a nasal mucosa area, the specific gene expression of the nasal mucosa is accurately regulated and controlled, an efficient and specific animal model is constructed, the efficient, stable and specific expression of the target protein in nasal mucosa tissues is realized, and the application prospect is wide. Therefore, reliable experimental tools and technical supports are provided for follow-up nasal disease mechanism research, new drug screening and gene function analysis.

The invention discloses a pharmaceutical composition for rhinitis health care and respiratory tract circulation improvement and a preparation method thereof.The pharmaceutical composition is prepared from pogostemon cablin, osmanthus fragrans, geranium, wild chrysanthemum flowers, semen armeniacae amarae, astragalus membranaceus, pericarpium citri reticulatae, platycodon grandiflorum, mint and menthol through processing and liquefying, and through the synergistic effect of all the pharmaceutical ingredients, the pharmaceutical composition has the effects of inducing resuscitation with fragrance, dissolving turbidity and dredging resuscitation; the condition of unsmooth ventilation of the nose can be effectively improved, and uncomfortable symptoms such as nasal obstruction can be relieved; the spreading and descending of lung qi are regulated, and the normal physiological function of the respiratory tract is maintained; the whole resistance of the body and local qi and blood nourishing of the nose are enhanced, and repair and regeneration of nose tissues are promoted; the invasion of external heat toxin to the nose is resisted, and the inflammatory response is relieved. Long-term use of the nasal mask can significantly promote respiratory tract microcirculation, enhance the immune defense function of the nose, and effectively prevent occurrence and recurrence of nasal diseases.

The invention provides a nasal cavity detecting and flushing nozzle, and relates to the field of nasal cavity nursing equipment. Comprising a nozzle body and an ultrasonic detection assembly. At least one liquid channel extending in the length direction of the spray head body is formed in the spray head body and used for supplying liquid into the nasal cavity through the liquid channel, so that the liquid in the nasal cavity is in a full state, and on one hand, the liquid serves as nasal cavity flushing liquid, and on the other hand, the liquid can serve as a coupling agent for ultrasonic detection. According to the scheme, in the daily cleaning and nursing process of the nasal cavity, the data of the internal structure of the nasal cavity can be obtained through the interventional ultrasonic detection technology, generation of a daily and real-time data model of the internal structure of the nasal cavity is facilitated, and the efficiency of cleaning and nursing of the nasal cavity is improved. Therefore, accurate diagnosis and treatment of nasal diseases are promoted.

This invention provides a method for preparing a thermosensitive gel for the prevention and treatment of nasal diseases and its application. By weight and volume percentage, it comprises recombinant human type III collagen, mussel adhesive protein, an anti-allergy agent, traditional Chinese medicine extracts, thermosensitive materials, and a sodium pyruvate-cocamidopropyl betaine ion-pair complex. This invention, by pre-forming the ion-pair complex, simultaneously solves the technical problems of existing nasal gels, such as poor anti-dilution ability, short adhesion time, and easy inactivation of active ingredients. The product is liquid below 30°C and can be sprayed for complete nasal coverage. At body temperature, it transforms into a gel within 2 minutes for long-lasting adhesion, exhibiting rapid anti-inflammatory, nasal patency-clearing, antipruritic, and mucosal repair effects. It is suitable for the prevention and treatment of allergic rhinitis and sinusitis, as well as nasal wound care, with significantly better efficacy than similar commercially available products.

The application relates to a preparation method and application of a novel composite hydrogel for improving nasal symptoms, and belongs to the technical field of hydrogel preparation. In order to solve the problems of easy inactivation, easy removal and strong stimulation of a volatile oil nasal delivery system in the prior art, the application provides a novel composite hydrogel for improving nasal symptoms. Through the synergistic effect of group functionalization mesoporous inorganic carriers, nanoemulsions and temperature-sensitive hydrogels, a double-response nasal drug delivery system is constructed, various natural medicinal volatile components can be widely loaded, drug stable protection, controlled release and target retention are realized, and a safe, efficient, good compliance, widely popularized innovative drug delivery strategy is provided for improving nasal symptoms, allergic rhinitis and other nasal diseases.

The invention belongs to the technical field of biological medicine, and discloses a compound exosome temperature-sensitive gel nasal delivery preparation which comprises the following components: exosome, poloxamer temperature-sensitive gel and functional components. The exosome, the poloxamer temperature-sensitive gel and the functional components are combined, and the exosome is wrapped in the poloxamer temperature-sensitive gel, so that the influence of the external environment on the biological activity of the exosome is avoided, and the stability of the exosome is improved; the poloxamer temperature-sensitive gel forms a gel layer in the nasal cavity and can be adhered to the mucous membrane of the nasal cavity for a long time, so that the residence time of the medicine is prolonged; the functional components and the exosome exert a synergistic treatment effect, the treatment effect on nasal diseases is improved, and compared with an existing nasal administration preparation, the compound exosome temperature-sensitive gel nasal administration preparation can solve the problems of single drug stability, single residence time, single treatment function and the like at the same time, and has a good application prospect. Important clinical application values and social and economic benefits are realized.

The present invention discloses a biomarker for predicting or evaluating the efficacy of anti-IL-4Rα monoclonal antibody in the treatment of nasal mucosa type 2 inflammation-related nasal diseases, characterized in that the biomarker is any one of TARC, TNF-α, TGF-β2, 15[S]-HETE, IL-25, CST1, CLC, ALOX15; optionally, the biomarker can also predict or evaluate the degree of inflammation of nasal mucosa type 2 inflammation-related nasal diseases. The biomarker of the present invention can quickly and accurately predict or evaluate the efficacy of anti-IL-4Rα monoclonal antibody in the treatment of nasal mucosa type 2 inflammation-related nasal diseases, filling the blank of the prior art and having great clinical value and economic value.

The invention provides traditional Chinese medicine powder for treating nasal cavity diseases and a preparation method of the traditional Chinese medicine powder. The effective components of the traditional Chinese medicine powder comprise radix angelicae, flos magnoliae, ligusticum wallichii, rhizoma acori graminei, pollen typhae, frankincense, myrrh and radix trichosanthis. Wherein the effective components comprise the following components in parts by weight: 1-2 parts of radix angelicae, 1-2 parts of flos magnoliae, 1-2 parts of ligusticum wallichii, 1-2 parts of rhizoma acori graminei, 1-2 parts of pollen typhae, 1-2 parts of frankincense, 1-2 parts of myrrh and 1-2 parts of radix trichosanthis. The traditional Chinese medicine powder is dipped by a dry cotton swab and smeared into the nasal cavity, is convenient to use, can quickly relieve nasal obstruction, and keeps a long-acting effect. Compared with an oral medicament, the compatibility and the compliance of a patient are higher; compared with a liquid liniment, the traditional Chinese medicine powder is not easy to flow and can be attached to an affected part for a long time to achieve a treatment effect.

The invention belongs to the field of traditional Chinese medicines, and discloses an external medicine for treating nasal diseases, which comprises the following raw material medicines: cocklebur fruit, mint, radix angelicae, centipeda minima, asarum, magnolia flower, divaricate saposhnikovia root, agastache rugosus, houttuynia cordata and borneol. According to different dosage forms, the external medicine disclosed by the invention not only can be adhered to the nose bridge, but also can be applied in the nasal cavity during use, and is convenient to use. Especially, the nasal mucosa cannot be directly stimulated when the nasal mucosa is externally attached to the nose bridge, discomfort brought by treatment to a patient is reduced, the nasal mucosa patch is easy to accept by the patient, and treatment compliance and safety of the patient are high. The externally applied medicine disclosed by some examples has a good curative effect on various chronic rhinitis, 550 patients with various nasal diseases are treated in the clinical diagnosis and treatment process, the clinical cure rate of acute rhinitis reaches 92%, the clinical cure rate of chronic rhinitis, nasosinusitis, allergic rhinitis and postnasal drip syndrome reaches 89%, and the cure rate of infantile adenoid hypertrophy and nasal polyp reaches 93%.